BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 10, 2023
Home » Topics » Disease categories and therapies » Infection

Infection
Infection RSS Feed RSS

Infection

Dmtc presents new Mip inhibitors for Q fever

Oct. 17, 2023
No Comments
Dmtc Ltd. has divulged macrophage infectivity potentiator (Mip)-related protein (bacterial) inhibitors reported to be useful for the treatment of Q fever.
Read More
Earth infected with pandemic

IDWeek 2023: Next pandemic preparedness – how to forecast and prevent

Oct. 16, 2023
By Coia Dulsat
No Comments
In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.
Read More
Creative rendition of SARS-CoV-2 virus particles.
Infection

PA-001 attenuates SARS-CoV-2 infection in preclinical models

Oct. 16, 2023
No Comments
Due to the continual emergence of SARS-CoV-2 mutants, there is an unmet clinical need for broad-spectrum treatments for COVID-19. A potential target for novel treatments is the S2 subunit of the SARS-CoV-2 spike (S) protein, which has been highly conserved across the different variants of the virus.
Read More
Infection

Protein-free innate immunity vaccine provides broad protection against otherwise lethal nosocomial antibiotic-resistant bacterial pathogens

Oct. 13, 2023
No Comments
In the U.S., hospital-borne antimicrobial-resistant nosocomial infections affect over 700,000 people every year causing more than 90,000 deaths along with a $28-45 billion financial burden. This commonly involves either methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus or carbapenem-resistant Acinetobacter baumannii.
Read More
Earth infected with pandemic
Infection

IDWeek 2023: Next pandemic preparedness – how to forecast and prevent

Oct. 13, 2023
By Coia Dulsat
No Comments
In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.
Read More
Infection

Nihon Nohyaku reports new compounds for fungal infections

Oct. 10, 2023
No Comments
Nihon Nohyaku Co. Ltd. has patented azole compounds reported to be useful for the treatment of fungal infections.
Read More
Infection

HBV-targeting epigenetic editors show durable and specific silencing of HBV in mice

Oct. 6, 2023
No Comments
Epigenetic editing approach used the endogenous cellular mechanisms for regulating gene expression, leading to durable modulation of transcription without affecting the DNA sequence. Chroma Medicine Inc. scientists recently presented a novel epigenetic editing strategy for the treatment of chronic hepatitis B virus (HBV) infection.
Read More
Red blood cells and coronavirus
Infection

Human blood vessels transplanted in mice reveal COVID-19 coagulation molecule

Oct. 6, 2023
By Subhasree Nag
No Comments
Recently, researchers at Cincinnati Children’s Hospital, in collaboration with colleagues in Japan, have developed a human vascular organoid model that accurately mimics the vascular damage caused by SARS-CoV-2.
Read More
Infection

Aerium licenses monoclonal antibodies against SARS-CoV-2

Oct. 5, 2023
No Comments
Aerium Therapeutics Inc. has licensed and commenced development of three monoclonal antibodies (MAbs) with broad and potent activity against the predominant variants of SARS-CoV-2, including those containing the F456L mutation, such as EG.5.1. These antibodies could provide an option to protect immunocompromised populations from severe COVID-19.
Read More
SARS-CoV-2 illustration turns from blue to red
Infection

BARDA funding supports Vir’s development of monoclonal antibody and delivery solutions for COVID-19 and pandemic preparedness

Oct. 5, 2023
No Comments
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response, has awarded Vir Biotechnology Inc. approximately $50 million in new funding to advance the development of novel monoclonal antibody (MAb) candidates and delivery solutions to widen the applicability of MAbs in COVID-19 and in pandemic preparedness and response.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 1542 1543 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for December 8, 2023.
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • Coronavirus, mRNA and syringe

    Off-target immune response from modified mRNA impacts future development

    BioWorld
    The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...
  • Feet and scale

    Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

    BioWorld
    Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing